TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda.

Humans Colorectal Neoplasms / genetics Rwanda Male Female Middle Aged Mutation Aged Tumor Suppressor Protein p53 / genetics Adult Aged, 80 and over Biomarkers, Tumor / genetics

TP53 Africa Colorectal cancer Consensus molecular subtypes Mismatch repair Mutation pattern Mutation spectrum Rwanda

Journal

BMC cancer

ISSN: 1471-2407

Titre abrégé: BMC Cancer

Pays: England

ID NLM: 100967800

Informations de publication

Date de publication:
11 Oct 2024

Historique:

received: 18 06 2024

accepted: 30 09 2024

medline: 12 10 2024

pubmed: 12 10 2024

entrez: 11 10 2024

Statut: epublish

Résumé

Mutations in the TP53 tumor suppressor gene are well-established drivers of colorectal cancer (CRC) development. However, data on the prevalence of TP53 variants and their association with consensus molecular subtype (CMS) classification in patients with CRC from Rwanda are currently lacking. This study addressed this knowledge gap by investigating TP53 mutation status concerning CMS classification in a CRC cohort from Rwanda. Formalin-fixed paraffin-embedded (FFPE) tissue blocks were obtained from 51 patients with CRC at the University Teaching Hospital of Kigali, Rwanda. Exons 4 to 11 and their flanking intron-exon boundaries in the TP53 gene were sequenced using Sanger sequencing to identify potential variants. The recently established immunohistochemistry-based classifier was employed to determine the CMS of each tumor. Sequencing analysis of cancerous tissue DNA revealed TP53 pathogenic variants in 23 of 51 (45.1%) patients from Rwanda. These variants were predominantly missense types (18/23, 78.3%). The most frequent were c.455dup (p.P153Afs*28), c.524G > A (p.R175H), and c.733G > A (p.G245S), each identified in three tumors. Trinucleotide sequence context analysis of the 23 mutations (20 of which were single-base substitutions) revealed a predominance of the [C > N] pattern among single-base substitutions (SBSs) (18/20; 90.0%), with C[C > T]G being the most frequent mutation (5/18, 27.8%). Furthermore, pyrimidine bases (C and T) were preferentially found at the 5' flanking position of the mutated cytosine (13/18; 72.2%). Analysis of CMS subtypes revealed the following distribution: CMS1 (microsatellite instability-immune) (6/51, 11.8%), CMS2 (canonical) (28/51, 54.9%), CMS3 (metabolic) (9/51, 17.6%), and CMS4 (mesenchymal) (8/51, 15.7%). Interestingly, the majority of TP53 variants were in the CMS2 subgroup (14/23; 60.1%). Our findings indicate a high frequency of TP53 variants in CRC patients from Rwanda. Importantly, these variants are enriched in the CMS2 subtype. This study, representing the second investigation into molecular alterations in patients with CRC from Rwanda and the first to explore TP53 mutations and CMS classification, provides valuable insights into the molecular landscape of CRC in this understudied population.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Formalin-fixed paraffin-embedded (FFPE) tissue blocks were obtained from 51 patients with CRC at the University Teaching Hospital of Kigali, Rwanda. Exons 4 to 11 and their flanking intron-exon boundaries in the TP53 gene were sequenced using Sanger sequencing to identify potential variants. The recently established immunohistochemistry-based classifier was employed to determine the CMS of each tumor.

RESULTS RESULTS

Sequencing analysis of cancerous tissue DNA revealed TP53 pathogenic variants in 23 of 51 (45.1%) patients from Rwanda. These variants were predominantly missense types (18/23, 78.3%). The most frequent were c.455dup (p.P153Afs*28), c.524G > A (p.R175H), and c.733G > A (p.G245S), each identified in three tumors. Trinucleotide sequence context analysis of the 23 mutations (20 of which were single-base substitutions) revealed a predominance of the [C > N] pattern among single-base substitutions (SBSs) (18/20; 90.0%), with C[C > T]G being the most frequent mutation (5/18, 27.8%). Furthermore, pyrimidine bases (C and T) were preferentially found at the 5' flanking position of the mutated cytosine (13/18; 72.2%). Analysis of CMS subtypes revealed the following distribution: CMS1 (microsatellite instability-immune) (6/51, 11.8%), CMS2 (canonical) (28/51, 54.9%), CMS3 (metabolic) (9/51, 17.6%), and CMS4 (mesenchymal) (8/51, 15.7%). Interestingly, the majority of TP53 variants were in the CMS2 subgroup (14/23; 60.1%).

CONCLUSION CONCLUSIONS

Our findings indicate a high frequency of TP53 variants in CRC patients from Rwanda. Importantly, these variants are enriched in the CMS2 subtype. This study, representing the second investigation into molecular alterations in patients with CRC from Rwanda and the first to explore TP53 mutations and CMS classification, provides valuable insights into the molecular landscape of CRC in this understudied population.

Identifiants

DOI: 10.1186/s12885-024-13009-8 PMID: 39394554

pubmed: 39394554

doi: 10.1186/s12885-024-13009-8

pii: 10.1186/s12885-024-13009-8

doi:

Substances chimiques

Tumor Suppressor Protein p53 0

TP53 protein, human 0

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1266

Subventions

Organisme : Japan Society for the Promotion of Science

ID : 20K07445

Informations de copyright

Références

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

doi: 10.3322/caac.21834 pubmed: 38572751

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer [Internet]. 2024 [cited 2024 Aug 18]. https://gco.iarc.who.int/today

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. [Internet]. 2024 [cited 2024 Apr 10]. https://gco.iarc.who.int/today

Rubagumya F, Costas-Chavarri A, Manirakiza A, Murenzi G, Uwinkindi F, Ntizimira C, et al. State of Cancer Control in Rwanda: past, Present, and Future opportunities. JCO Glob Oncol. 2020;6(6):1171–7.

doi: 10.1200/GO.20.00281 pubmed: 32701365

Rubagumya F, Wilson B, Manirakiza A, Mutabazi E, Ndoli A, Rudakemwa D. Financial toxicity: unveiling the Burden of Cancer Care on patients in Rwanda. Oncologist. 2024;29(3):e345–50.

doi: 10.1093/oncolo/oyad291 pubmed: 37897406

Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021;22(7):1002–13.

doi: 10.1016/S1470-2045(21)00199-6 pubmed: 34048685

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

doi: 10.3322/caac.21820 pubmed: 38230766

Manirakiza F, Rutaganda E, Yamada H, Iwashita Y, Rugwizangoga B, Seminega B, et al. Clinicopathological characteristics and Mutational Landscape of APC, HOXB13, and KRAS among Rwandan patients with colorectal Cancer. Curr Issues Mol Biol. 2023;45(5):4359–74.

doi: 10.3390/cimb45050277 pubmed: 37232746 pmcid: 10217012

Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73.

pubmed: 22943008 pmcid: 3418538

Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E, et al. Heterogeneity of TP53 mutations and P53 protein residual function in Cancer: does it Matter? Front Oncol. 2020;10:593383.

doi: 10.3389/fonc.2020.593383 pubmed: 33194757 pmcid: 7655923

Dong Z, Zheng L, Liu W, Wang C. Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis. Cancer Manag Res. 2018;10:1341–9.

doi: 10.2147/CMAR.S164892 pubmed: 29872345 pmcid: 5973318

Wang Q, Wei F, Lv G, Li C, Liu T, Hadjipanayis CG, et al. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin. BMC Cancer. 2013;13(1):521.

doi: 10.1186/1471-2407-13-521 pubmed: 24182354 pmcid: 3840673

Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. 2012;37(1):3–8.

pubmed: 23115424 pmcid: 3470295

Eisenstein M. A visual guide to restoring the guardian of the genome. Nature. 2022;603(7899).

Liebl MC, Hofmann TG. The role of p53 signaling in Colorectal Cancer. Cancers (Basel). 2021;13(9):2125.

doi: 10.3390/cancers13092125 pubmed: 33924934

Fischer M. Census and evaluation of p53 target genes. Vol. 36, Oncogene. 2017.

Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15(1):13–30.

doi: 10.1038/nrclinonc.2017.151 pubmed: 28948977

Kim KM, Ahn AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer. 2022;22(1):1–17.

doi: 10.1186/s12885-022-10039-y

Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 2014;24(1):52–60.

doi: 10.1016/j.gde.2013.11.014 pubmed: 24657537 pmcid: 3990474

Degasperi A, Zou X, Dias Amarante T, Martinez-Martinez A, Koh GCC, Dias JML et al. Substitution mutational signatures in whole-genome–sequenced cancers in the UK population. Sci (80-). 2022;376(6591).

Shimizu T, Marusawa H, Matsumoto Y, Inuzuka T, Ikeda A, Fujii Y, et al. Accumulation of somatic mutations in TP53 in gastric epithelium with helicobacter pylori infection. Gastroenterology. 2014;147(2):407–e4173.

doi: 10.1053/j.gastro.2014.04.036 pubmed: 24786892

Nzitakera A, Surwumwe JB, Ndoricyimpaye EL, Uwamungu S, Uwamariya D, Manirakiza F, et al. The spectrum of TP53 mutations in Rwandan patients with gastric cancer. Genes Environ. 2024;46(1):8.

doi: 10.1186/s41021-024-00302-y pubmed: 38459566 pmcid: 10921722

Beale RCL, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. Comparison of the Differential Context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation Spectra in vivo. J Mol Biol. 2004;337(3).

Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15(9):585–98.

doi: 10.1038/nrg3729 pubmed: 24981601 pmcid: 6044419

De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–8.

doi: 10.1038/nm.3174

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

doi: 10.1038/nm.3967 pubmed: 26457759 pmcid: 4636487

Pesántez D, ten Hoorn S, Machado I, García-Albéniz X, Rodríguez-Salas N, Heredia-Soto V, et al. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402. JNCI J Natl Cancer Inst. 2023;115(12):1497–505.

doi: 10.1093/jnci/djad120 pubmed: 37405857

Li Y, Yao Q, Zhang L, Mo S, Cai S, Huang D, et al. Immunohistochemistry-based Consensus Molecular subtypes as a prognostic and predictive biomarker for adjuvant chemotherapy in patients with stage II colorectal Cancer. Oncologist. 2020;25(12):e1968–79.

doi: 10.1002/ONCO.13521 pubmed: 32926498 pmcid: 8186407

Sawayama H, Miyamoto Y, Ogawa K, Yoshida N, Baba H. Investigation of colorectal cancer in accordance with consensus molecular subtype classification. Ann Gastroenterol Surg. 2020;4(5):528–39.

doi: 10.1002/ags3.12362 pubmed: 33005848 pmcid: 7511559

Lafarge MW, Domingo E, Sirinukunwattana K, Wood R, Samuel L, Murray G, et al. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. npj Precis Oncol. 2024;8(1):89.

doi: 10.1038/s41698-024-00580-3 pubmed: 38594327 pmcid: 11003957

Trinh A, Trumpi K, De Sousa E, Melo F, Wang X, de Jong JH, Fessler E, et al. Practical and robust identification of Molecular subtypes in Colorectal Cancer by immunohistochemistry. Clin Cancer Res. 2017;23(2):387–98.

doi: 10.1158/1078-0432.CCR-16-0680 pubmed: 27459899

Thanki K, Nicholls ME, Gajjar A, Senagore AJ, Qiu S, Szabo C, et al. Consensus Molecular subtypes of Colorectal Cancer and their clinical implications. Int Biol Biomed J. 2017;3(3):105–11.

pubmed: 28825047 pmcid: 5557054

Rejali L, Seifollahi Asl R, Sanjabi F, Fatemi N, Asadzadeh Aghdaei H, Saeedi Niasar M, et al. Principles of Molecular Utility for CMS classification in Colorectal Cancer Management. Cancers (Basel). 2023;15(10):2746.

doi: 10.3390/cancers15102746 pubmed: 37345083 pmcid: 10216373

Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.

doi: 10.1038/s41392-021-00762-6 pubmed: 34980884 pmcid: 8724284

Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015;28(3):414–27.

doi: 10.1038/modpathol.2014.122 pubmed: 25216220

Li X, Larsson P, Ljuslinder I, Ling A, Löfgren-Burström A, Zingmark C, et al. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry. Pathol Res Pract. 2021;220:153379.

doi: 10.1016/j.prp.2021.153379 pubmed: 33721619

WHO Classification of Tumours Editorial Board; Digestive System Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer. 2019. 85–95 p.

Natsume H, Szczepaniak K, Yamada H, Iwashita Y, Gędek M, Šuto J, et al. Non-CpG sites preference in G:C > A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to east Asian countries (China and Japan). Genes Environ off J Japanese Environ Mutagen Soc. 2023;45(1):1.

den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, Mcgowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9.

doi: 10.1002/humu.22981

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in Cancer. J Mol Diagnostics. 2017;19(1):4–23.

doi: 10.1016/j.jmoldx.2016.10.002

Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.

doi: 10.1038/nature15393 pubmed: 26432245

Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993):92–100.

doi: 10.1038/s41586-023-06045-0 pubmed: 38057664

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753

Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835–44.

doi: 10.1093/nar/gkz972 pubmed: 31777943

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.

doi: 10.1038/nature12477 pubmed: 23945592 pmcid: 3776390

Parente P, Grillo F, Vanoli A, Macciomei MC, Ambrosio MR, Scibetta N, et al. The Day-To-Day practice of MMR and MSI Assessment in Colorectal Adenocarcinoma: what we know and what we still need to explore. Dig Dis. 2023;41(5):746–56.

doi: 10.1159/000531003 pubmed: 37231848

ICGC Data Portal. Colorectal Cancer - CN [Internet]. International Cancer Genome Consortium. 2023. https://dcc.icgc.org/projects/COCA-CN

Ganesh K, Wu C, O’Rourke KP, Szeglin BC, Zheng Y, Sauvé C-EG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25(10):1607–14.

doi: 10.1038/s41591-019-0584-2 pubmed: 31591597 pmcid: 7385919

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an Open platform for exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401–4.

doi: 10.1158/2159-8290.CD-12-0095 pubmed: 22588877

Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25(1):154–60.

doi: 10.1038/cdd.2017.180 pubmed: 29099487

DeBoever C, Tanigawa Y, Lindholm ME, McInnes G, Lavertu A, Ingelsson E, et al. Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. Nat Commun. 2018;9(1):1612.

doi: 10.1038/s41467-018-03910-9 pubmed: 29691392 pmcid: 5915386

Toguchida J, Yamaguchi T, Dayton SH, Beaughamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with Sarcoma. N Engl J Med. 1992;326(20):1301–8.

doi: 10.1056/NEJM199205143262001 pubmed: 1565143

KAGAWA H, HATAKEYAMA K, SHIOMI A, HINO H, MANABE S, YAMAOKA Y, et al. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. Biomed Res. 2022;43(6):201–9.

doi: 10.2220/biomedres.43.201 pubmed: 36517022

Purcell RV, Schmeier S, Lau YC, Pearson JF, Frizelle FA. Molecular subtyping improves prognostication of stage 2 colorectal cancer. BMC Cancer. 2019;19(1):1155.

doi: 10.1186/s12885-019-6327-4 pubmed: 31775679 pmcid: 6882162

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, et al. Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO open. 2019;4(3):e000523.

doi: 10.1136/esmoopen-2019-000523 pubmed: 31321083 pmcid: 6598553

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying Colorectal Cancer by Tumor Location rather than sidedness highlights a Continuum in Mutation profiles and Consensus Molecular subtypes. Clin Cancer Res. 2018;24(5):1062–72.

doi: 10.1158/1078-0432.CCR-17-2484 pubmed: 29180604

Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, et al. Targeting the oncogenic p53 mutants in Colorectal Cancer and other solid tumors. Int J Mol Sci. 2019;20(23):5999.

doi: 10.3390/ijms20235999 pubmed: 31795192 pmcid: 6929124

Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in Colorectal Cancer and its implication for Therapy. Cancers (Basel). 2021;13(10):2296.

doi: 10.3390/cancers13102296 pubmed: 34064974 pmcid: 8150459

Tong DR, Zhou W, Katz C, Regunath K, Venkatesh D, Ihuegbu C, et al. P53 frameshift mutations couple loss-of-function with unique neomorphic activities. Mol Cancer Res. 2021;19(9):1522–33.

doi: 10.1158/1541-7786.MCR-20-0691 pubmed: 34045312 pmcid: 8419077

Liang J, Huang K, Cheng Y, Hsu H, Cheng A, Hsu C, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002;97(4):451–7.

doi: 10.1002/ijc.1637 pubmed: 11802206

Hsiue EH-C, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH et al. Targeting a neoantigen derived from a common TP53 mutation. Science (80-). 2021;371(6533).

Yang C, Lou G, Jin W-L. The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies. Signal Transduct Target Ther. 2021;6(1):219.

doi: 10.1038/s41392-021-00635-y pubmed: 34083505 pmcid: 8175382

Chasov V, Zaripov M, Mirgayazova R, Khadiullina R, Zmievskaya E, Ganeeva I, et al. Promising New Tools for Targeting p53 mutant cancers: Humoral and Cell-based immunotherapies. Front Immunol. 2021;12:707734.

doi: 10.3389/fimmu.2021.707734 pubmed: 34484205 pmcid: 8411701

Everitt AV, Hilmer SN, Brand-Miller JC, Jamieson HA, Truswell AS, Sharma AP, et al. Dietary approaches that delay age-related diseases. Clin Interv Aging. 2006;1(1):11–31.

doi: 10.2147/ciia.2006.1.1.11 pubmed: 18047254 pmcid: 2682451

Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020;122(7):943–52.

doi: 10.1038/s41416-019-0721-1 pubmed: 32042067 pmcid: 7109142

Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022;7(1):391.

doi: 10.1038/s41392-022-01251-0 pubmed: 36522308 pmcid: 9755275

Keshavarz M, Xie K, Schaaf K, Bano D, Ehninger D. Targeting the hallmarks of aging to slow aging and treat age-related disease: fact or fiction? Mol Psychiatry. 2023;28(1):242–55.

doi: 10.1038/s41380-022-01680-x pubmed: 35840801

Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, et al. Impact of Consensus Molecular Subtype on Survival in patients with metastatic colorectal Cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019;37(22):1876–85.

doi: 10.1200/JCO.18.02258 pubmed: 31042420 pmcid: 6675593

Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2017;35(15suppl):3511–3511.

doi: 10.1200/JCO.2017.35.15_suppl.3511

Mooi JK, Wirapati P, Asher R, Lee CK, Savas P, Price TJ, et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Ann Oncol. 2018;29(11):2240–6.

doi: 10.1093/annonc/mdy410 pubmed: 30247524

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of Tumor Site, type of mutation, and Adjuvant Treatment. J Clin Oncol. 2005;23(30):7518–28.

doi: 10.1200/JCO.2005.00.471 pubmed: 16172461

Miller M, Shirole N, Tian R, Pal D, Sordella R. The evolution of TP53 mutations: from loss-of-function to separation-of-function mutants. J cancer Biol Res. 2016;4(4):1091.

pubmed: 28191499 pmcid: 5298884

Thota R, Yang M, Pflieger L, Schell MJ, Rajan M, Davis TB, et al. APC and TP53 mutations predict Cetuximab Sensitivity across Consensus Molecular subtypes. Cancers (Basel). 2021;13(21):5394.

doi: 10.3390/cancers13215394 pubmed: 34771559